Soy Reduces Bone Turnover Markers in Women During Early Menopause

A Randomized Controlled Trial

Thozhukat Sathyapalan, Mo Aye, Alan S. Rigby, William D. Fraser, Natalie J. Thatcher, Eric S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators, their role in bone turnover is unclear. The primary outcome was assessing changes in plasma bone turnover markers. The secondary outcomes were assessing changes in cardiovascular risk markers including insulin resistance, blood pressure, and lipid profile. We performed a double-blind randomized parallel study in which 200 women within 2 years after the onset of their menopause were randomized to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (SP), daily for 6 months. There was a significant reduction in type I collagen crosslinked beta C-telopeptide (βCTX) (bone-resorption marker) with SPI supplementation (0.40 ± 0.17 versus 0.15 ± 0.09 μg/L; p < 0.01) compared to SP supplementation (0.35 ± 0.12 versus 0.35 ± 0.13 μg/L; p = 0.92) after 6 months. There was also a significant reduction in type I procollagen-N-propeptide (P1NP) (bone formation marker) with SPI supplementation (50.5 ± 25.0 versus 34.3 ± 17.6 μg/L; p < 0.01), more marked between 3 and 6 months. Following SPI there was a significant reduction in fasting glucose, fasting insulin, insulin resistance, and systolic blood pressure whereas no significant changes in these parameters was observed with SP. There were no significant changes in fasting lipid profile and diastolic blood pressure with either preparation. There was a significant increase in TSH and reduction in free thyroxine (p < 0.01) with SPI supplementation though free tri-iodothyronine was unchanged. In conclusion, soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a less magnitude. There was a significant improvement of cardiovascular risk markers, but a significant increase in TSH and reduction in free thyroxine after SPI supplementation indicating a detrimental effect on thyroid function.

Original languageEnglish
Pages (from-to)157-164
Number of pages8
JournalJournal of Bone and Mineral Research
Volume32
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017
Externally publishedYes

Fingerprint

Soybean Proteins
Bone Remodeling
Menopause
Randomized Controlled Trials
Isoflavones
Blood Pressure
Fasting
Collagen Type I
Thyroxine
Insulin Resistance
Bone Density Conservation Agents
Lipids
Selective Estrogen Receptor Modulators
Bone and Bones
Bone Resorption
Osteogenesis
Thyroid Gland
Estrogens
Insulin
Glucose

Keywords

  • BONE TURNOVER MARKERS
  • CADIOVASCULAR RISK MARKERS
  • P1NP
  • PHYTOESTROGENS
  • SOY ISOFLAVONES
  • THYROID FUNCTION
  • βCTX

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Soy Reduces Bone Turnover Markers in Women During Early Menopause : A Randomized Controlled Trial. / Sathyapalan, Thozhukat; Aye, Mo; Rigby, Alan S.; Fraser, William D.; Thatcher, Natalie J.; Kilpatrick, Eric S.; Atkin, Stephen.

In: Journal of Bone and Mineral Research, Vol. 32, No. 1, 01.01.2017, p. 157-164.

Research output: Contribution to journalArticle

Sathyapalan, Thozhukat ; Aye, Mo ; Rigby, Alan S. ; Fraser, William D. ; Thatcher, Natalie J. ; Kilpatrick, Eric S. ; Atkin, Stephen. / Soy Reduces Bone Turnover Markers in Women During Early Menopause : A Randomized Controlled Trial. In: Journal of Bone and Mineral Research. 2017 ; Vol. 32, No. 1. pp. 157-164.
@article{a39aea761bfd4c54bd61e6e56ca4eba2,
title = "Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial",
abstract = "Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators, their role in bone turnover is unclear. The primary outcome was assessing changes in plasma bone turnover markers. The secondary outcomes were assessing changes in cardiovascular risk markers including insulin resistance, blood pressure, and lipid profile. We performed a double-blind randomized parallel study in which 200 women within 2 years after the onset of their menopause were randomized to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (SP), daily for 6 months. There was a significant reduction in type I collagen crosslinked beta C-telopeptide (βCTX) (bone-resorption marker) with SPI supplementation (0.40 ± 0.17 versus 0.15 ± 0.09 μg/L; p < 0.01) compared to SP supplementation (0.35 ± 0.12 versus 0.35 ± 0.13 μg/L; p = 0.92) after 6 months. There was also a significant reduction in type I procollagen-N-propeptide (P1NP) (bone formation marker) with SPI supplementation (50.5 ± 25.0 versus 34.3 ± 17.6 μg/L; p < 0.01), more marked between 3 and 6 months. Following SPI there was a significant reduction in fasting glucose, fasting insulin, insulin resistance, and systolic blood pressure whereas no significant changes in these parameters was observed with SP. There were no significant changes in fasting lipid profile and diastolic blood pressure with either preparation. There was a significant increase in TSH and reduction in free thyroxine (p < 0.01) with SPI supplementation though free tri-iodothyronine was unchanged. In conclusion, soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a less magnitude. There was a significant improvement of cardiovascular risk markers, but a significant increase in TSH and reduction in free thyroxine after SPI supplementation indicating a detrimental effect on thyroid function.",
keywords = "BONE TURNOVER MARKERS, CADIOVASCULAR RISK MARKERS, P1NP, PHYTOESTROGENS, SOY ISOFLAVONES, THYROID FUNCTION, βCTX",
author = "Thozhukat Sathyapalan and Mo Aye and Rigby, {Alan S.} and Fraser, {William D.} and Thatcher, {Natalie J.} and Kilpatrick, {Eric S.} and Stephen Atkin",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/jbmr.2927",
language = "English",
volume = "32",
pages = "157--164",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Soy Reduces Bone Turnover Markers in Women During Early Menopause

T2 - A Randomized Controlled Trial

AU - Sathyapalan, Thozhukat

AU - Aye, Mo

AU - Rigby, Alan S.

AU - Fraser, William D.

AU - Thatcher, Natalie J.

AU - Kilpatrick, Eric S.

AU - Atkin, Stephen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators, their role in bone turnover is unclear. The primary outcome was assessing changes in plasma bone turnover markers. The secondary outcomes were assessing changes in cardiovascular risk markers including insulin resistance, blood pressure, and lipid profile. We performed a double-blind randomized parallel study in which 200 women within 2 years after the onset of their menopause were randomized to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (SP), daily for 6 months. There was a significant reduction in type I collagen crosslinked beta C-telopeptide (βCTX) (bone-resorption marker) with SPI supplementation (0.40 ± 0.17 versus 0.15 ± 0.09 μg/L; p < 0.01) compared to SP supplementation (0.35 ± 0.12 versus 0.35 ± 0.13 μg/L; p = 0.92) after 6 months. There was also a significant reduction in type I procollagen-N-propeptide (P1NP) (bone formation marker) with SPI supplementation (50.5 ± 25.0 versus 34.3 ± 17.6 μg/L; p < 0.01), more marked between 3 and 6 months. Following SPI there was a significant reduction in fasting glucose, fasting insulin, insulin resistance, and systolic blood pressure whereas no significant changes in these parameters was observed with SP. There were no significant changes in fasting lipid profile and diastolic blood pressure with either preparation. There was a significant increase in TSH and reduction in free thyroxine (p < 0.01) with SPI supplementation though free tri-iodothyronine was unchanged. In conclusion, soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a less magnitude. There was a significant improvement of cardiovascular risk markers, but a significant increase in TSH and reduction in free thyroxine after SPI supplementation indicating a detrimental effect on thyroid function.

AB - Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators, their role in bone turnover is unclear. The primary outcome was assessing changes in plasma bone turnover markers. The secondary outcomes were assessing changes in cardiovascular risk markers including insulin resistance, blood pressure, and lipid profile. We performed a double-blind randomized parallel study in which 200 women within 2 years after the onset of their menopause were randomized to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (SP), daily for 6 months. There was a significant reduction in type I collagen crosslinked beta C-telopeptide (βCTX) (bone-resorption marker) with SPI supplementation (0.40 ± 0.17 versus 0.15 ± 0.09 μg/L; p < 0.01) compared to SP supplementation (0.35 ± 0.12 versus 0.35 ± 0.13 μg/L; p = 0.92) after 6 months. There was also a significant reduction in type I procollagen-N-propeptide (P1NP) (bone formation marker) with SPI supplementation (50.5 ± 25.0 versus 34.3 ± 17.6 μg/L; p < 0.01), more marked between 3 and 6 months. Following SPI there was a significant reduction in fasting glucose, fasting insulin, insulin resistance, and systolic blood pressure whereas no significant changes in these parameters was observed with SP. There were no significant changes in fasting lipid profile and diastolic blood pressure with either preparation. There was a significant increase in TSH and reduction in free thyroxine (p < 0.01) with SPI supplementation though free tri-iodothyronine was unchanged. In conclusion, soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a less magnitude. There was a significant improvement of cardiovascular risk markers, but a significant increase in TSH and reduction in free thyroxine after SPI supplementation indicating a detrimental effect on thyroid function.

KW - BONE TURNOVER MARKERS

KW - CADIOVASCULAR RISK MARKERS

KW - P1NP

KW - PHYTOESTROGENS

KW - SOY ISOFLAVONES

KW - THYROID FUNCTION

KW - βCTX

UR - http://www.scopus.com/inward/record.url?scp=84992609001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992609001&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2927

DO - 10.1002/jbmr.2927

M3 - Article

VL - 32

SP - 157

EP - 164

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -